Violation of interactions between MALAT1 and SRSF2 ultimately lead to inhibition of pre-mRNA alternative splicing and expressions of genes involved in cancer development, and such an effect might explain both the decreased tumor aggression activity and better survival rates in patients with various cancer types who are minor T-allele carriers (32). The gene discussed is MALAT1; the disease is neoplasm.